Pfizer CEO, Albert Bourla, said in nationally televised interview that it is necessary to fend off waning protection.
This article was originally published in ContagionLive.com
(Adobe Stock)
Yesterday, on the nationally broadcast television show, Face the Nation, Pfizer CEO Albert Bourla said he expected people to need a fourth dose of the vaccine to prevent another wave of COVID-19.
Back in January, a study published in The Lancet found that 3 doses of the Pfizer-BioNTech (BNT162b2) or AstraZeneca (AZD1222) COVID-19 vaccines effectively neutralized the Omicron variant.
However since the emergence of Omicron in the last few months, waning protection in the vaccines has been a developing issue as the case loads increased in the early part of 2022.
Pfizer has been working on a booster dose to address the variants.
"The variants are coming," Bourla said. "Omicron was the first to be able to evade in a skillful way the immune protection we were given, but we also know the duration of the protection doesn’t last very long. What we are trying to do—and we are working very diligently right now—is to not only make a vaccine that protects against all variants including Omicron but something that also protects for a year."
When asked if a fourth dose was necessary, Bourla said, ”It is necessary a fourth booster, right now; the protection we are getting from the third is good enough; it is actually quite good for hospitalizations and deaths; it’s not that good against infections.”
No timeline has been set for the booster dose for the variants yet, but Bourla says the company will be ready with the manufacturing whenever a decision is made.
In the same interview, he said we are going to have to learn how to live with the virus. When asked if he thought if the COVID-19 vaccine would need to be administered annually like the influenza vaccine Bourla said, “I think so."
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.